Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

494 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries.
Khunti K, Caputo S, Damci T, Dzida GJ, Ji Q, Kaiser M, Karnieli E, Liebl A, Ligthelm RJ, Nazeri A, Orozco-Beltran D, Pan C, Ross SA, Svendsen AL, Vora J, Yale JF, Meneghini LF; SOLVE Study Group. Khunti K, et al. Among authors: ross sa. Diabetes Obes Metab. 2012 Dec;14(12):1129-36. doi: 10.1111/j.1463-1326.2012.01665.x. Epub 2012 Aug 30. Diabetes Obes Metab. 2012. PMID: 22830956
Weight beneficial treatments for type 2 diabetes.
Meneghini LF, Orozco-Beltran D, Khunti K, Caputo S, Damçi T, Liebl A, Ross SA. Meneghini LF, et al. Among authors: ross sa. J Clin Endocrinol Metab. 2011 Nov;96(11):3337-53. doi: 10.1210/jc.2011-1074. Epub 2011 Sep 7. J Clin Endocrinol Metab. 2011. PMID: 21900381 Review.
Practical guidance to insulin management.
Meneghini L, Artola S, Caputo S, Damci T, Dzida G, Kaiser M, Khunti K, Liebl A, Ligthelm R, Maran A, Orozco-Beltran D, Ross S, Yale JF. Meneghini L, et al. Prim Care Diabetes. 2010 Apr;4 Suppl 1:S43-56. doi: 10.1016/S1751-9918(10)60008-3. Prim Care Diabetes. 2010. PMID: 20394891
Impact of weight gain on outcomes in type 2 diabetes.
Ross SA, Dzida G, Vora J, Khunti K, Kaiser M, Ligthelm RJ. Ross SA, et al. Curr Med Res Opin. 2011 Jul;27(7):1431-8. doi: 10.1185/03007995.2011.585396. Epub 2011 May 23. Curr Med Res Opin. 2011. PMID: 21599553 Review.
Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial.
Ross SA, Caballero AE, Del Prato S, Gallwitz B, Lewis-D'Agostino D, Bailes Z, Thiemann S, Patel S, Woerle HJ, von Eynatten M. Ross SA, et al. Diabetes Obes Metab. 2015 Feb;17(2):136-44. doi: 10.1111/dom.12399. Epub 2014 Nov 19. Diabetes Obes Metab. 2015. PMID: 25298165 Clinical Trial.
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189511 Clinical Trial.
494 results